SCHEMBL607341

SCHEMBL607341

OC(CN1CCNCC1)Cn1c2ccc(Cl)cc2c2cc(Cl)ccc21

nearest known ligand 0.78

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 3/20 0.76
NLRP1 Q9C000 1/20 0.76
BAX Q07812 2/20 0.72
MAPT P10636 2/20 0.70
TP53 P04637 1/20 0.70
CYP3A4 P08684 1/20 0.70
ALOX15 P16050 1/20 0.70
MAPK1 P28482 1/20 0.70
LMNA P02545 3/20 0.60
ALDH1A1 P00352 2/20 0.60
KDM4E B2RXH2 1/20 0.60
HTT P42858 1/20 0.60
IDO1 P14902 1/20 0.55
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
POLB P06746 1/20 0.48
PER2 O15055 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6823233 0.90 RAD52 (0.86) RAD52NLRP1BAXMAPTTP53
SCHEMBL16604024 0.84 RAD52 (0.74) RAD52NLRP1MAPTTP53MAPK1
SCHEMBL16211042 0.84 RAD52 (0.76) RAD52NLRP1BAXMAPTTP53
SCHEMBL29432619 0.84 BAX (1.00) RAD52NLRP1BAXMAPTTP53
SCHEMBL29991749 0.84 BAX (1.00) RAD52NLRP1BAXMAPTTP53
SCHEMBL609455 0.84 BAX (1.00) RAD52NLRP1BAXMAPTTP53
SCHEMBL6819364 0.84 RAD52 (0.76) RAD52NLRP1MAPTMAPK1LMNA
SCHEMBL609012 0.84 BAX (1.00) RAD52NLRP1BAXMAPTTP53
SCHEMBL6816191 0.84 RAD52 (0.76) RAD52NLRP1MAPTMAPK1LMNA
SCHEMBL29716701 0.84 BAX (1.00) RAD52NLRP1BAXMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP claimed
US-8410110-B2 9-(piperazinylalkyl) carbazoles as Bax-modulators MERCK SERONO SA (CH) 2013-04-02 US disclosed
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2012-02-16 US disclosed
US-8053436-B1 9-(piperazinylalkyl) carbazoles as bax-modulators MERCK SERONO SA (CH) 2011-11-08 US disclosed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP disclosed
EP-1237887-A1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS Applied Research Systems ARS Holding N.V. (AN) 2002-09-11 EP disclosed
WO-2001029028-A1 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS BCL2, BAX, BAD RAD52 3656/4885NLRP1 2445/4885BAX 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.